Study: Casdatifan demonstrates durable tumor responses in heavily pretreated patients with advanced kidney cancer

Study: Casdatifan, a new generation HIF-2α blocker, demonstrated durable tumor responses in heavily pretreated patients with advanced kidney cancer. The findings link treatment activity to HIF-2α biology and biomarker changes, supporting precision medicine approaches.

Raccontata daeurekalert.org